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ESSENTIALS 
 The metabolic integration processes required for platelet activation are unclear. 
 The metabolic plasticity of human platelets are investigated 
 Activated platelets exhibit a glycolytic phenotype while preserving mitochondrial 
function 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 Platelets can switch freely between glucose/glycogen and fatty acids to support 
aggregation 
 
SUMMARY  
Background. Platelet activation is an energy-dependent process, but the type and integrated 
use of metabolic fuels required to drive activation remains unclear.  
Objective. To dissect the metabolic fuel and pathway plasticity required for platelet 
activation.  
Methods. Platelet Oxygen Consumption rate (OCR) and Extracellular Acidification Rate (ECAR) 
were measured as markers of oxidative phosphorylation (OXPHOS) and glycolysis 
respectively. Glucose and glycogen were quantified by enzyme-coupled fluorometric assay.  
Results: Blood platelets switch freely between glycolysis and OXPHOS using either glucose or 
fatty acids at rest.  The transition of platelets from quiescent to activated state promotes a 
rapid uptake of exogenous of glucose associated with a shift to a predominant glycolytic 
phenotype coupled with a minor rise in mitochondrial oxygen consumption. Consistent with 
this metabolic plasticity, under nutrient limiting conditions, platelets utilised glucose, 
glycogen or fatty acids independently to support activation. Importantly, the glycolytic switch 
occurred even in the absence of extracellular glucose, originating from endogenous 
glycogen. Focusing on the relative flexibility of mitochondrial fuel oxidation of glucose and 
fatty acids, we found that inhibition of a single fuel oxidation was compensated by the 
increased oxidation of the other, but when oxidation is inhibited, glycolysis is upregulated. 
Glutamine had little contribution to mitochondrial oxygen consumption. Analysis of the 
platelet functional dependency on ATP from different pathways demonstrated that inhibition 
of both fuel oxidation and glycolysis were required to prevent agonist driven platelet 
activation. 
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Conclusion: Platelets have significant metabolic fuel and pathway flexibility, but preferentially 
use glycolysis for ATP generation when activated.  
 
Keywords: Glycolysis; oxidative phosphorylation; Fatty acids; Glycogen; Blood Platelets.  
 
INTRODUCTION 
Blood platelets play a critical role in the cessation of bleeding upon vascular injury. Exposure 
of sub endothelial matrix proteins at areas of vessel wall damage triggers platelet activation, 
adhesion and aggregation. The subsequent release of soluble platelet agonists triggers 
platelet aggregation to ensure rapid haemostasis. Conversely, the inappropriate activation of 
platelets can promote vascular inflammation, atherogenesis and arterial thrombosis (1,2). The 
transition of platelets from a quiescent to an activated state requires dramatic changes in the 
availability of ATP (3–7). Early studies used 6-14C-glucose to confirm that platelets possess 
the molecular machinery necessary to generate ATP through both glycolysis and oxidative 
phosphorylation (OXPHOS) of glucose (8,9).  These early data have now been confirmed by 
modern metabolic analysis (10) which has provided an important framework of 
understanding of platelet metabolism.  While platelets express glucose transporters and 
glucose is an established metabolic substrate, platelets also have the capacity to take up and 
oxidise fatty acids (11) and glutamine as sources of ATP generation at rest and in response 
to activatory stimuli (10).  Despite this, knowledge of platelet metabolism remains 
incomplete, since the contribution of internal stores of glycogen has been overlooked.  This 
knowledge is crucial since regulation of metabolic pathways is influenced by the relative 
abundance of glucose, fatty acids (FA) glutamine and internal stores of energy, and the 
ability of cells to access, and switch between, these substrates.  Thus, while platelets have the 
potential for metabolic flexibility, we have only a partial understanding of fuel choices by 
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platelets and whether these are functionally specific. Similarly while platelet mitochondrial 
dysfunction has been reported in a number of disorders including type-2-diabetes (12,13), 
sickle cell disease and sepsis (14,15), the overall importance to, and flexibility of, 
mitochondria in platelet function remains poorly understood.  To address this knowledge 
gap, we have examined if platelet activation was associated with regulated changes in fuel 
metabolism, which in turn were linked to specific functional responses.  Crucially, we have 
explored the extent to which endogenous reserves of fuel, in the form of glycogen, 
contribute to platelet metabolic function. 
 
MATERIALS AND METHODS: 
Reagents 
Studies were approved by the Hull York Medical School Ethics Committee and were 
conducted in accordance with the Declaration of Helsinki. Antimycin A from Streptomyces sp. 
(antimycin A), rotenone, Cell-Tak Cell & Tissue Adhesive was from Scientific Laboratory 
Supplies Limited (Hessle, UK). Glucose standard 5mM/L was from Analox (Stourbridge, UK). 
Nicotinamide adenine dinucleotide phosphate (NADP) and Hexokinase/Glucose-6-Phosphate 
Dehydrogenase was from Roche (West Sussex, UK). Collagen Reagens HORM® Suspension 
(KRH) is from Takeda Cambridge Limited (Cambridge, United Kingdom). All other chemicals 
were from Sigma-Aldrich (Dorset, UK). 
 
Platelet isolation and aggregation 
Human washed platelets were prepared and aggregation and ATP secretion were tested as 
described previously (16). For experiments in glucose-restricted media, glucose was excluded 
from the modified Tyrode’s buffer. For metabolic analyses, platelets were prepared as 
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described previously (17) and then diluted to 1x108 platelets/mL in modified Tyrode’s buffer 
(15mM NaCl, 0.55 mM NaH2PO4, 2.7mM KCl, 0.5mM MgCl2 and 3mg/L phenol red).  
 
Glucose consumption by platelets in vitro 
Washed platelets (2.5x108 platelets/mL) were stimulated with thrombin (0.01-0.1U/mL) and 
aliquots removed at 0, 1, 3, 5, 7 and 9 minutes for glucose analysis using enzyme-coupled 
fluorometric assay modified from (18). Briefly, the conversion of glucose to phosphoglucono-
δlactone results in the production of highly fluorescent NADPH. The change in the 
fluorescence is proportional to the amount of glucose, which can be detected with a 
fluorescence microplate reader with excitation/emission of 340/460nm. 
 
Measuring platelet oxygen consumption and glycolytic rate 
The XFp format Seahorse extracellular flux analyser (Agilent Seahorse Bioscience, MA, USA) 
was used to measure platelet oxygen consumption (OCR) and extracellular acidification rate 
(ECAR). XFp micro-plates were coated with Cell-Tak (17), washed with PBS and dried 30 
minutes prior to experiments. Washed platelets (1x108 platelets/ml; 50µL) were seeded on the 
plate as described previously (17). The volume of each well volume was adjusted to 180 µL 
with XFp assay medium. Platelets were stimulated with thrombin (0.01 or 0.1U/mL) in the 
presence or absence of oligomycin (1µM), FCCP (2µM), antimycin/rotenone (2.5µM), 2-
deoxyglucose (50mM), etomoxir (40µM), BPTES (3µM) and UK5099 (2µM) (Figure S1). The 
results were standardised for µg proteins using Microplate DCTM protein assay. Unless stated 
otherwise, the Seahorse Glycolytic Stress Test, Mitochondrial Stress Test, Cell Phenotype Test 
and Mitochondrial Fuel Flexibility Tests were carried out according to manufacturers 
instructions (Agilent Seahorse Bioscience, MA, USA). % Platelet mitochondrial dependency, 
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capacity and flexibility for glucose and fatty acid oxidation calculated as recommended by 
the manufacturer (Agilent Seahorse Bioscience, MA, USA);  
 
Glucose: % Dependency= (
                  
                                 
)*100%;  
%Capacity= (1- 
                          
                                 
)*100%;  
%Flexibility= %Capacity- %Dependency.  
Fatty acids:  % Dependency= (
                    
                                 
)*100%;  
%Capacity= (1- 
                        
                                 
)*100%;  
%Flexibility= %Capacity- %Dependency. 
 
Glycogen Determination 
Platelet glycogen content, at rest and after thrombin stimulation, was determined in glucose 
depleted Tyrode’s buffer using the acid hydrolysis method (19).  Briefly, platelet samples were 
subjected to sonication to release all the glycogen. The supernatant was acid-hydrolysed with 
4M HCl, boiled for 90 minutes before being neutralised with 2M Na2CO3. The liberated 
glucose was quantified using enzyme-coupled fluorometric assay. 
 
Statistical analysis 
Student T-test and analysis of variance (Anova) followed by either Dunn’s multiple 
comparisons or Holm-Sidak multiple comparison tests. Non-linear regression (dose-response 
curve) was used to compare the concentration of agonist (EC50) that gives half of the 
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maximal response. Data presented as mean ± SEM for assays with three technical replicates 
per biological replicate or mean ± SD for three biological replicates. All statistical analyses 
were performed using GraphPad Prism. * Represents p<0.05, ** p<0.01, *** p<0.001, 
****p<0.0001 
 
RESULTS 
Thrombin-induced platelet activation stimulates glucose uptake 
Thrombin stimulation induced rapid glucose depletion from the platelet containing-medium 
(Figure 1). Under basal conditions, platelets absorbed glucose at a steady state (0.03±0.03 
µmol/min/108 cells), which increased 15-fold (0.5±0.2 µmol/min/108 cells; p<0.05) over the 
first minute after stimulation with thrombin (0.1U/ml; Figure 1Ai, Aii), before returning to 
basal levels 3 minutes post stimulation (Figure 1Ai, Aii).  Using a concentration of thrombin 
(0.01U/ml) to induce a threshold aggregation response, we observed biphasic depletion of 
glucose that was linked to the aggregation response (Figure 1Bi, Bii). The rate of glucose 
depletion increased 8-fold (0.03±0.004 μmol/min/108 to 0.28±0.03 μmols/min/108; p<0.01) 
within the first minute and was maintained for up to 5 minutes as aggregation plateaued. 
Interestingly, glucose uptake then increased again to 0.57±0.06 μmols/min/108 (p<0.01 
compared to basal) as the secondary aggregation response was initiated (Figure 1Bi, Bii). The 
rate of glucose depletion for the secondary aggregation response (5-7min) was significantly 
higher (p<0.05) than the initial aggregation response (1-3 min). These data suggest that 
thrombin induced platelet activation stimulates dose-dependent glucose uptake, which 
coincides with the different phases of the aggregation response (Figure 1A, B). To confirm 
this link between platelet function and glucose metabolism, we measured ECAR as readout of 
glycolysis. Thrombin stimulated a glycolysis as evidence by a transient increase in ECAR 
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(p<0.0001; Figure 1Ci, Cii).  Inhibition of TxA2 generation by indomethacin caused a modest 
but significant reduction in ECAR (4.2±0.7 to 3.4±0.6 mpH/min/μg protein; P<0.05). In 
contrast inhibition of ADP signalling with apyrase was without effect. These data suggest that 
platelets actively take up external glucose in response to physiological stimuli that drive 
energy-demanding functions.  
 
Thrombin-induced maximal glycolytic capacity requires both PAR1 and PAR4 receptors 
We next examined the maximal glycolytic capacity (20) of platelets (maximal rate of 
conversion of glucose to lactate under stressed conditions), at rest and during activation 
using the ‘XFp glycolytic stress test’. The basal ECAR was increased to 1.63 ± 0.6 
mpH/min/μg protein (p<0.01) with glucose addition (5.6 mM), giving the basal glycolytic 
function (Figure 2Ai, Aii). The injection of oligomycin, to inhibit all mitochondrial ATP 
generation, increased ECAR to 4.0 ± 0.2 mpH/min/μg protein (p<0.001), which was taken as 
maximal glycolysis in resting platelets. The addition of 2-DG ablated the ECAR, indicating that 
the ECAR was from glycolysis and that non-glycolytic ECAR was negligible (Figure 2Ai, Aii). 
Stimulation with thrombin (0.1U/mL) (in the presence of glucose) caused a 10-fold increase in 
ECAR (5.9±0.4mpH/min/μg protein; p<0.001) (Figure 2Bi, Bii), which began to fall over the 
next 25 minutes. The subsequent treatment with oligomycin increased ECAR to 5.43 ± 0.4 
mpH/min/μg protein. Since this increase was no different to that induced by thrombin, it 
suggested that thrombin induced maximal glycolytic capacity. Thrombin activation of 
platelets requires ligation of both PAR1 and PAR4 (21) and so we next examined their relative 
contribution to platelet glycolytic capacity (Figure S2A and B). The PAR1 and PAR4 specific 
peptides induced dose-dependent glycolytic responses (Figure 2C, D). However, neither 
peptide stimulated ECAR to the same extent as thrombin at maximal doses. Consistent with 
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these observations, oligomycin was able to increase ECAR further in both PAR1 
(5.8±0.1mpH/min/μg protein; p<0.001) and PAR4 (4.0±0.1 mpH/min/μg protein; p<0.001). 
These data suggest that platelets have sufficient glycolytic scope to generate ATP in the 
absence of mitochondrial function, which can be increased significantly by platelet activation.  
 
Platelet activation induces a glycolytic phenotype while preserving mitochondrial 
function  
The inhibition of mitochondrial ATP synthesis with oligomycin increased glycolysis (Figure 2), 
suggesting that OXPHOS contributes to ATP generation. Therefore, we examined the 
partitioning of glucose to glycolysis and OXPHOS. To create conditions where OCR and ECAR 
were mostly glucose-dependent, platelets were treated with etomoxir, an inhibitor of 
carnitine palmitoyltransferase-1 (10,22), to eliminate the contribution of fatty acid β-oxidation 
to OCR.  When stimulated with thrombin (0.1U/mL), OCR rose from 1.3±0.02 to 2.0±0.03 
pmol/min/μg protein (p<0.01; Figure 3Ai, Aii).  This rise was abolished by the addition of 
inhibitors of complex I/III of the mitochondrial respiratory chain, antimycin A and rotenone 
(A/R). This increase in OXPHOS was accompanied by a 4-fold increase in ECAR (1.7±0.1 to 
7.1±0.72mpH/min/μg protein; p<0.01) (Figure 3Bi, Bii). Next, an energy phenotype 
experiment (Agilent Seahorse Bioscience, MA, USA) was performed without etomoxir to 
explore whether metabolic changes were the consequence of the inhibition of endogenous 
fatty acids oxidation (Figure 3D). Basally, platelets utilise glycolysis and OXPHOS almost 
equally (Figure 3D). Activation of platelets led to increased activity of both aerobic glycolysis 
and OXPHOS (Figure 3A, B, D), but critically there was a shift to a glycolysis- dominated 
phenotype (almost 3 fold change in ECAR) where oxidative phosphorylation changed only 
minimally (Figures 3C and S2B).  
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Endogenous reserves can fuel platelet activation  
After establishing the importance of glucose metabolism in platelets, the role of endogenous 
fuels in the absence of exogenous glucose was explored. The omission of glucose from the 
medium, containing no other energy substrates, had no effect on thrombin induced platelet 
aggregation (Figure 4Ai) or ATP secretion (Figure 4Aii) or collagen-induced aggregation and 
secretion (Figure S2C), but was accompanied by a significant decrease in intracellular 
glycogen (23.5±4.3 to 10.6±3.5 µg/108 cell) (p<0.05; Figure 4B). Since externally sourced 
glucose was not a prerequisite for platelet activation, the relationship between exogenous 
glucose and endogenous glycogen in thrombin-stimulated platelets was explored (Figure 
4Ci). In the absence of external sources of energy, thrombin increased ECAR (0.7±0.1 to a 
maximum of 4.6±0.4mpH/min/μg protein; p< 0.001), which was unaffected by oligomycin. In 
contrast, when replete with exogenous glucose platelets were able to respond to oligomycin 
by increasing ECAR (Figure 4Cii). Given that these data suggested that glycogen could 
support platelet function but require exogenous glucose to sustain glycolysis, the metabolic 
fate of glycogen upon platelet activation was explored. In contrast to experiments performed 
in the presence of external glucose (Figure 3Ai), the omission of extracellular glucose, 
inhibition of β-oxidation caused a sustained and significant fall in OCR (Figure 4Di), 
suggesting that in the absence of exogenous glucose, endogenous fatty acids are critical to 
maintaining basal OXPHOS. Nevertheless, thrombin (0.1U/mL) increased OCR by 2.5 fold 
(2.1±0.1 pmol/min/µg protein; p<0.01) and ECAR by 10-fold (4.6±1.3mpH/min/µg protein; 
p<0.01; Figure 4D). Thus, when platelets are deprived of extracellular glucose, thrombin still 
provokes a switch to a glycolytic phenotype with the preserved mitochondrial function and 
that glycogen shares similar metabolic fate as glucose.    
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Platelet mitochondrial fuel flexibility  
Having established that platelets can take up glucose, but readily utilise endogenous 
glycogen and fatty acids in the absence of glucose, the relative flexibility of platelets in 
oxidising glucose, endogenous fatty acids and glutamine were explored. Flexibility is defined 
as the difference between the capacity that exists for a given pathway to increase to a 
maximal and the absolute minimum dependency on that pathway. We first demonstrated 
that glutamine contributed minimally to mitochondrial oxygen consumption (Figure S3A), 
leaving glucose and FA as the main oxidative fuels. Thrombin-induced aggregation was 
unchanged by the UK5099 (an inhibitor of glucose oxidation) or etomoxir when used alone 
or in combination (Figure 5A), indicative of metabolic plasticity. Next, the platelet flexibility to 
oxidise glucose at rest and after activation were investigated measuring OCR (Figure 5) and 
ECAR (Figure S3). UK5099 reduced basal OCR by 36.0± 3.5% (Figure 5Bi) indicating platelet 
dependency on glucose oxidation. However, there is the capacity for this to increase to 
58.3±2.1% when fatty acid and glutamine oxidation are inhibited (Figure 5Bii). The difference 
between the full capacity and dependency is equivalent to the platelets flexibility on glucose 
oxidation, 22.2±0.6% of total OCR (Figure 5Biii).  By contrast, activation by thrombin 
(0.1U/mL) increased platelet dependency on glucose oxidation, accounting for 48.6±3.8% of 
total OCR (Figure 5Ci).  Overall capacity to oxidise glucose did not change from that seen in 
resting platelets (54.3±1.5% of total OCR; Figure 5Cii and Ciii) indicating that activation is 
supported by platelets’ ability to utilize metabolic scope.  
 
Next the platelet flexibility to oxidise endogenous fatty acids was measured at rest and after 
activation. Inhibition of fatty acid oxidation by etomoxir reduced platelet OCR by 30.63±7.9% 
(Figure 5Di). The subsequent inhibition of glucose and glutamine oxidation indicated that full 
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capacity of platelets to oxidise fatty acids was 56.0±7.4% of total OCR (Figure 5Dii). These 
data indicate that platelets can increase the proportion of OCR dedicated to fatty acid 
oxidation by 25.4±6.9% in the absence of other fuels (Figure 5Diii). Thrombin (0.1U/mL) did 
not have significant effect on platelet dependency (37.7±4.0%), capacity (54.3±1.5%) and 
flexibility (23.2±0.5%) on fatty acid oxidation (Figure 5E) compared to unstimulated platelets. 
This may be due to the limited pool of metabolically available endogenous fatty acids. The 
inhibition of fatty acid and glucose/glutamine oxidation pathways independently, did not 
affect ECAR. However, inhibiting all major fuel oxidation increased ECAR significantly (p<0.05; 
SF 3B, C). These data indicate that inhibition of a single fuel oxidation can be compensated 
by the increased oxidation of the other. Critically when all the fuel oxidation is inhibited, 
glycolysis is upregulated for the compensation of energy generation.  
 
Mitochondrial function of resting and activated platelets  
The fuel flexibility of platelets prompted the investigation of platelet functional dependency 
on ATP from glycolysis and mitochondrial OXPHOS. The individual inhibition of total 
mitochondrial ATP synthesis with oligomycin, or glucose metabolism with 2-DG did not affect 
platelet aggregation.  However, almost total inhibition of platelet aggregation was achieved 
in combination (Figure 6Ai, Aii) suggesting that platelets have sufficient glycolysis to support 
the need for ATP even when mitochondrial ATP machinery is manipulated. Having 
established this flexibility, we next performed a detailed analysis of mitochondrial 
components of respiration in resting platelets. Platelet mitochondrial components of 
respiration were measured with the sequential injection of oligomycin, to provide the OCR 
linked to ATP synthesis, FCCP, a mitochondrial uncoupler, which reveals maximal respiration, 
and a combination of antimycin A and rotenone (Figure 6Bi). ATP-linked OCR, non-
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mitochondrial OCR, proton leak and reserve respiratory capacity were 76.6±5.0%, 11.6±7.0%, 
11.7±6.0% and 34.5± 7.0%, respectively (Figure 6Bii). Thrombin (0.1U/mL) increased OCR 
from 2.1±0.2 to 3.1±0.4 pmol/min/µg protein (p<0.001; Figure 6Biii, Biv), which was 
associated with increased ATP-linked OXPHOS, increased maximal respiration and reserve 
capacity. Inhibition of platelet derived TxA2 generation by indomethacin (10μM) significantly 
reduced thrombin-induced OCR, ATP-linked OCR, maximal respiration and reserve capacity 
(all p<0.001 compared to thrombin alone). The omission of glucose did not significantly alter 
any of the parameters (Figure 6D). 
Thus, platelets use their reserve respiratory capacity in addition to increasing glycolysis to 
satisfy the increased need for ATP synthesis in response to thrombin stimulation, which 
requires platelet-derived TxA2 to support mitochondrial function (Figure 6C). Furthermore, 
glycogen alone can fully support the mitochondrial function during platelet activation (Figure 
6D). 
 
Sf 4b  
DISCUSSION 
Our knowledge of the metabolic fuel choices and how key metabolic pathways are regulated 
to support platelet functions are unclear. In the present study, we demonstrate that platelets 
use both glucose/glycogen and endogenous FA to support glycolysis and OXPHOS as means 
of maintaining baseline ATP demand. Upon platelet activation, the cells adopt a glycolytic 
phenotype regardless of the nutrient availability. However, this change to a glycolytic state 
during cellular activation is underpinned by a remarkable metabolic versatility, whereby under 
normal physiological conditions, platelets are able to move freely between mitochondrial 
glucose and FA oxidation.  
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Glucose is an abundant, readily available nutrient for platelets in situ, yet our current 
understanding of platelet glucose metabolism is limited in terms of the functional 
requirements for glucose and the glycolytic capacity of platelets under stressed conditions. 
The abundance of GLUT3 suggests that a sustained glucose transport into platelets is 
guaranteed even in a low glucose environment, and is indirectly indicative of the importance 
of glucose to platelet function, both at rest and following activation (23–25).  Recent studies 
have now demonstrate that the loss of GLUT3 can fundamentally diminish key elements of 
platelet function (26). Thus, focusing on carbohydrate metabolism, we found that platelet 
glucose uptake was potentially linked to the phase of activation in response to external 
stimuli. Consistent with this observation, thrombin stimulation caused a receptor mediated 
significant increase in glycolysis. The maximal glycolytic rate of resting platelets was less than 
that of thrombin-stimulated, which required both PAR1 and PAR4 receptors (Figure 1-2). 
Activatory cells have a metabolic ‘capacity’, which enables them to respond quantitatively and 
sensitively to changing energy demands, despite the fact that under normal conditions, they 
operate at a lower metabolic rate (27). Platelets clearly display this type of glycolytic capacity, 
as glycolysis increases in response to the inhibition of OXPHOS, suggesting a Pasteur effect-
type of metabolic compensation, and that platelets utilise this ‘capacity’ to support activation.  
 
Next, we demonstrated a clearer understanding of the biological role of glycogen, the 
interplay between glycogen and exogenous glucose and their metabolic fate in platelets.  We 
found that glycogen alone can support platelet activation and that it shared similar metabolic 
fate with glucose. Focusing on the partitioning of glucose and glycogen in glycolysis and 
OXPHOS, or data confirm  previous studies that the pathways of glycolysis and glucose 
oxidation are present in platelets (10,28–30). In addition to this, the current study has 
reconfirmed that activated platelets adopt a glycolytic phenotype while preserving the 
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mitochondrial function, regardless of fuel availability.  Importantly, our data has established 
for the first time that this phenotype occurs in the absence of externally supplied glucose, 
indicating that endogenous reserves can serve as a fuel source (Figure 3-4). These data 
suggest that the functional responses were driven by choosing aerobic glycolysis over 
OXPHOS of glucose and glycogen consistent with a ‘Warburg’ or aerobic glycolytic 
phenotype (31,32). The commitment to a less efficient energy-generating pathway as 
glycolysis is not unusual and has been reported in granulocytes, dendritic cells (33), 
monocytes (34) and macrophages (35). Thus, a glycolytic switch upon stimulation observed in 
blood platelets may represent a conserved immunometabolic pattern in developmentally 
related cells of blood lineages. While many nucleated immune cells switch to Warburg 
metabolism to support proliferation (36), it is likely that the low efficiency but rapid rate of 
ATP production by glycolysis is required to support a rapid change in energy demand in 
response to platelet activation (37). The preserved mitochondrial function while presenting a 
glycolytic phenotype suggests an ATP requirement as well as redox metabolism beyond 
glycolysis to maintain cell survival (38–40).   
 
Metabolism of glucose, fatty acids and amino acids converge in mitochondria, where fuel 
oxidation can be modified in response to changes in the availability of nutrients and the 
energy demand of the cell under various conditions (41). Focusing on platelet mitochondrial 
function (Figure 5-6), we show that platelets can switch freely between glucose and fatty acid 
oxidation both at rest and under activated conditions. Earlier studies suggest that fatty acid 
-oxidation may compensate for a reduction of glycolysis (42).  However, we show that when 
oxidation of glucose and fatty acids are restricted, platelets up-regulate aerobic glycolysis to 
meet the energy demand for functional responses, indicating not only fuel, but metabolic 
pathway flexibility in order to respond to a thrombotic signal. The majority of oxygen 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
consumed by platelets is linked to ATP synthesis, with only modest contributions from 
proton leak and non-mitochondrial functions. Platelet activation leads to increased oxidative 
metabolism facilitated by the presence of a significant mitochondrial ‘reserve capacity’, which 
provides additional scope for mitochondrial function necessary for responding to increases in 
ATP demand in times of work or stress (43). Interestingly, maximal thrombin induced OCR 
required the release of platelet derived TxA2, suggesting that agents secondary to the initial 
platelet activation is required to promote maximal OXPHOS. The omission of glucose did not 
affect mitochondrial function, again highlighting the metabolic plasticity of platelets. This 
presents the possibility that platelets possess uniqueness in terms of metabolic flexibility 
when compared to other immune cells. For example, the inhibition of fatty acid oxidation 
blocked T cell differentiation into Treg whereas supplementation with fatty acids supported its 
function (44). Similarly, the polarization of M2 macrophages is fatty acid dependent and the 
inhibition of fatty acid oxidation drives M2 macrophages to M1 state (45). Mature dendritic 
cells have both OXPHOS and aerobic glycolysis where the inhibition of glycolysis prevents 
dendritic cell maturation (46). For platelets, such flexibility may be important to ensure 
function in a range of environments including within the thrombus, where the availability of 
nutrients and oxygen may be limited (47,48). The availability of endogenous glycogen, fatty 
acids and the flexibility to produce sufficient ATP solely from glycolysis or OXPHOS in 
platelets indicate a potential survival mechanism for the most adverse microenvironments 
(34,49) Alternatively, it is possible that flux and use of specific metabolic pathways are linked 
to distinct functions. Detailed bioenergetic profiling of platelet immune and angiogenic 
functions will be required to fully appreciate how the metabolic microenvironment including 
availability of oxygen and nutrients determine the influence of platelets on multiple aspects 
of vascular biology.  
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In summary, this study describes a detailed systematic analysis of fuel choice made by 
human platelets at rest and under activating conditions. Of note, platelets adopt a glycolytic 
phenotype when stimulated with thrombin regardless of the nutrient availability and 
thrombin dose. Most importantly, this study describes a remarkable metabolic plasticity, 
switching freely between substrates and metabolic pathways, of blood platelets under 
physiological conditions. A better understanding of platelet metabolism and modulation of 
fuel availability may offer new opportunities to optimise long-term storage conditions.  
Moreover, there is increasing evidence showing that transition between resting to activated 
state of the activatory cells require specific metabolic patterns (36,50) to support functional 
changes (10,34,51). In this context, improving our understanding of platelet metabolism and 
its regulation could lead to the development of novel therapeutic targets for treating arterial 
thrombosis and potentially other inflammatory diseases. 
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Figure Legends 
 
FIGURE 1. Thrombin-induced platelet activation stimulates glucose uptake. 
(A) Human washed platelets (3x108 platelets/ml) were stimulated with thrombin (0.1U/ml) 
followed by measurement of aggregation and glucose depletion from the medium. (i) 
Representative aggregation trace of three independent experiments. (ii) Glucose depletion 
rate from the medium over a 9 minutes period after thrombin stimulation. Results were 
expressed as rate of glucose depletion (μmols/min/108 platelets), mean ± SEM, n=3. (B) As in 
(A) except platelets were stimulated with thrombin (0.01U/ml). (C) The Extracellular 
Acidification Rate (ECAR) was measured for platelets treated with thrombin (0.1U/ml), in the 
presence and absence of apyrase (2U/ml) and indomethacin (10μM). (i) Average ECAR plotted 
over time. (ii) Average ECAR from C(i) with data presented as mean ± SEM, n=3. *p<0.05; 
**p<0.01; ****p<0.0001 
 
FIGURE 2. Thrombin-induced maximal glycolytic capacity requires both PAR1 and PAR4 
receptors 
(A) ECAR of human platelets was measured in Glycolytic Stress Test with sequential injection 
of glucose (5.6mM), oligomycin (1μM) and 2-deoxy glucose (2-DG, 50mM). (i) Average ECAR 
plotted over time.  (ii) Average ECAR quantified from A(i). The average was taken after each 
injection. (B) As in (A) except platelets were stimulated with thrombin (0.1U/ml). (C) ECAR of 
human platelets was measured with 2.5, 5, and 10μM of PAR1. (i) Average ECAR plotted over 
time. (ii) Average ECAR from C(i). (D) ECAR of human platelets was measured with 10, 20, 
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and 50μM of PAR4. (i) Average ECAR plotted over time. (ii) Average ECAR from D(i).  All data 
presented as mean ± SEM, n=3. *p<0.05; **p<0.01; ***p<0.001 
 
FIGURE 3. Platelet activation induces a glycolytic phenotype while preserving 
mitochondrial function  
(A) Oxygen Consumption Rate (OCR) was measured with sequential injection of etomoxir 
(40µM), thrombin (0.1/0.01 U/ml), antimycin A & rotenone (A/R; 2.5 μM) and 2-DG. (i) 
Average OCR of platelets plotted over time. The glucose/glycogen dependent oxygen 
consumption was separated by the addition of etomoxir. Non-mitochondrial OCR was 
accounted by the OCR insensitive to a combination of A/R.  (ii) Average OCR quantified from 
A(i). (B) ECAR of platelets measured simultaneously with (A). 2-DG was added to correct for 
non-glycolytic extracellular acidification. (C) Fold changes in glucose-dependent OCR & ECAR 
over basal was quantified from (A) and (B). The proportions are calculated for the values that 
were corrected for non-mitochondrial OCR & non-glycolytic ECAR. (D) XFp Cell Phenotype 
Test was carried out in the absence of etomoxir. The ratio between OCR and ECAR was 
plotted under basal and stressed conditions. Stressed OCR and ECAR were measured with 
combination of oligomycin and FCCP in the presence of 0.1U/ml thrombin. All data shown as 
mean ± SEM, n=3. **p<0.01 
 
FIGURE 4. Endogenous reserves can fuel platelet activation  
(A) Human washed platelet aggregation and ATP secretion was tested in the presence and 
absence (+/-) of glucose in the media. (i) Dose response curve of platelets stimulated with 
thrombin in +/- glucose media. EC50 was compared for each dose with data shown as mean 
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± SD, n=3. (B) Platelet glycogen level before after thrombin (0.1U/ml) stimulation in glucose-
free media. Data shown as mean ± SD. (C) ECAR of human platelets was measured in 
Glycolytic Stress Test with thrombin (0.1U/ml) in the presence or absence of glucose. (i) 
Average ECAR plotted over time with sequential injection of 0.1U/ml thrombin, oligomycin 
and 2-DG in glucose-free media. (ii) Average EACR plotted over time with sequential injection 
of 0.1U/ml thrombin, glucose, oligomycin and 2-DG in glucose-free media. (D) OCR was 
measured in glucose-free media with sequential injection of etomoxir, thrombin (0.1 U/ml), 
A/R and 2-DG. (i) Average OCR plotted over time. (ii) Average OCR quantified from D(i). (iii) 
Average ECAR measured simultaneously with D(i) and plotted over time. (iv) Average ECAR 
quantified from D(iii). (v) Fold changes in glycogen-dependent OCR & ECAR over basal was 
quantified from D(i) and D(iii). The proportions are calculated for the values that were 
corrected for non-mitochondrial OCR & non-glycolytic ECAR. Data expressed as mean ± 
SEM, n=3. *p<0.05; **p<0.01; ***p<0.001 
 
FIGURE 5. Platelet mitochondrial fuel flexibility  
(A) Human washed platelets were stimulated with thrombin (0.1U/ml) followed by 
measurement of aggregation in the presence of etomoxir and UK5099 (2µM). (i) 
Representative aggregation trace of three independent experiments. (ii) % Platelet 
aggregation was quantified from A(i) with data expressed as mean ± SD, n=3. (B) Platelet 
mitochondrial flexibility for glucose oxidation was measured using XFp Mitochondrial Fuel 
Flexibility Test. (i) Average OCR was plotted over time for platelet dependency to oxidise 
glucose. Basal OCR was established before the sequential injection of UK5099 and the 
combination of etomoxir and BPTES. (ii) Average OCR was plotted over time for platelet 
capacity to oxidise glucose. Basal OCR was established before the sequential injection of the 
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combination of etomoxir and BPTES followed by UK5099. (iii) % Platelet mitochondrial 
dependency, capacity and flexibility for glucose oxidation calculated from B(i) and B(ii). The 
average was taken after each injection. (C) As in (B) except platelets were stimulated with 
thrombin (0.1U/ml). (D) Platelet mitochondrial flexibility for fatty acid oxidation was measured 
using XFp Mitochondrial Fuel Flexibility Test. (i) Average OCR was plotted over time for 
platelet dependency to oxidise fatty acids.  Basal OCR was established before the sequential 
addition of etomoxir and the combination of UK5099 and BPTES. (ii) Average OCR was 
plotted over time for platelet capacity to oxidise fatty acids.  Basal OCR was established 
before the sequential addition of the combination of UK5099 and BPTES followed by 
etomoxir. (iii) % Platelet mitochondrial dependency, capacity and flexibility for endogenous 
fatty acid oxidation calculated from D(i) and D(ii). The average was taken after each injection. 
(E) As in (D) except platelets were stimulated with thrombin (0.1U/ml). Data shown as mean 
± SEM, n=3. 
 
FIGURE 6. Mitochondrial function of resting and activated platelets  
(A) Human washed platelets were stimulated with thrombin (0.1U/ml) followed by 
measurement of aggregation in the presence of oligomycin and 2-DG. (i) Representative 
aggregation trace of three independent experiments. (ii) % Platelet aggregation was 
quantified from A (i) with data expressed as mean ± SD, n=3.  (B) Platelet mitochondrial 
function was measured using XFp Mitochondrial Stress Test. (i) Average OCR was plotted 
over time for platelet with sequential injection of oligomycin, FCCP and antimycin & 
rotenone (A/R). (ii) ATP-linked OCR, non-mitochondrial OCR, proton leak and reserve capacity 
was calculated as % of basal OCR from B(i). (iii) As in B(i) except platelets were stimulated 
with thrombin (0.01U/ml). (iv) Average OCR quantified from B(iii).The average was taken after 
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each injection. (C) As in B(iii) except platelets were treated with Indomethacin (10μM). (D) As 
in B(iii) except for the absence of glucose in the medium. Data shown as mean ± SEM, n=3. 
*p<0.05; **p<0.01;p<0.001; ****p<0.0001 
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